Wall Street analysts expect Medtronic (MDT) to post quarterly earnings of $1.45 per share in its upcoming report, which indicates a year-over-year decline of 7.6%. Revenues are expected to be $8.44 billion, down 1.3% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a c ...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of lifeDUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD ...

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivot ...

Medtronic (MDT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this medical device company have returned +8.2%, compared to the Zacks S&P 500 composite's +5% change. During this period, the Zacks Medical - Products industry, which Medtronic falls in, has gained 3.5%. The key question now is: What could be the stock's future direction?Although media repor ...

In the latest trading session, Medtronic (MDT) closed at $83.52, marking a +0.82% move from the previous day. This move outpaced the S&P 500's daily loss of 0.02%. Meanwhile, the Dow lost 0.21%, and the Nasdaq, a tech-heavy index, added 0.29%.Shares of the medical device company witnessed a gain of 3.38% over the previous month, beating the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 1.29%.The upcoming earnings release of Medtronic will be of great interest to investor ...

Company hosting in-person R&D day event, focused on atrioventricular interval modulation ("AVIM") therapy, including the unmet need in hypertension, mechanism of action, clinical results and design of the BACKBEAT study in New York City on June 11, 2024 NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today repor ...

Medtronic (MDT) is expected to release fourth-quarter fiscal 2024 results on May 23 before the opening bell.Let’s delve into the factors that might have influenced this medical device major’s results in this to-be-reported quarter. However, it’s worth taking a look at MDT’s previous-quarter performance first.Impressive Surprise HistoryThe company posted adjusted earnings per share (EPS) of $1.30 in the last reported quarter, which topped the Zacks Consensus Estimate by 3.17%. Medtronic beat earnings estimat ...

DUBLIN, May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's fourth quarter and full fiscal year 2024, which ended on Frida ...

Arecor Therapeutics plc("Arecor" or the "Company") ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor's development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier liv ...

The latest trading session saw Medtronic (MDT) ending at $81.76, denoting a +0.09% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.03% for the day. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq added 1.19%.Prior to today's trading, shares of the medical device company had lost 3.39% over the past month. This has lagged the Medical sector's loss of 1.41% and the S&P 500's loss of 1.57% in that time.Market participants will be closely foll ...